- Home
- KLRS vs AACG Comparison
KLRS vs AACG Comparison
Compare KLRS & AACG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- AACG
- Stock Information
- Founded
- KLRS 2019
- AACG 1999
- Country
- KLRS United States
- AACG China
- Employees
- KLRS N/A
- AACG N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- AACG Other Consumer Services
- Sector
- KLRS Health Care
- AACG Real Estate
- Exchange
- KLRS Nasdaq
- AACG Nasdaq
- Market Cap
- KLRS 46.0M
- AACG 51.9M
- IPO Year
- KLRS N/A
- AACG N/A
- Fundamental
- Price
- KLRS $6.31
- AACG $1.09
- Analyst Decision
- KLRS Strong Buy
- AACG
- Analyst Count
- KLRS 3
- AACG 0
- Target Price
- KLRS $21.50
- AACG N/A
- AVG Volume (30 Days)
- KLRS 147.9K
- AACG 23.8K
- Earning Date
- KLRS 11-12-2025
- AACG 11-12-2025
- Dividend Yield
- KLRS N/A
- AACG N/A
- EPS Growth
- KLRS N/A
- AACG N/A
- EPS
- KLRS N/A
- AACG N/A
- Revenue
- KLRS N/A
- AACG $39,316,403.00
- Revenue This Year
- KLRS N/A
- AACG N/A
- Revenue Next Year
- KLRS N/A
- AACG N/A
- P/E Ratio
- KLRS N/A
- AACG N/A
- Revenue Growth
- KLRS N/A
- AACG 11.62
- 52 Week Low
- KLRS $2.14
- AACG $0.70
- 52 Week High
- KLRS $12.90
- AACG $2.58
- Technical
- Relative Strength Index (RSI)
- KLRS 57.79
- AACG 43.43
- Support Level
- KLRS $6.04
- AACG $1.18
- Resistance Level
- KLRS $7.07
- AACG $1.36
- Average True Range (ATR)
- KLRS 0.66
- AACG 0.11
- MACD
- KLRS 0.08
- AACG -0.00
- Stochastic Oscillator
- KLRS 64.94
- AACG 33.33
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.